University of Warwick spin-out company, Medherant, has appointed Laboratoires Plasto Santé to manufacture its drug delivery patches, which will be based on novel transdermal drug delivery technology.
Ibuprofen
These drug delivery devices will be used for clinical studies of ibuprofen patches and will be based on Medherant’s proprietary TEPI Patch technology. The studies, planned to start in autumn this year, will test safety and efficacy of the patches.
“We’re delighted to have Laboratoires Plasto Santé as our contract manufacturer at this exciting time in our company’s growth,” commented Nigel Davis, CEO of Medherant. “Combining our TEPI Patch technology with Laboratoires Plasto Santé’s product manufacturing expertise will enable us to start clinical trials and facilitate rapid growth of our library of patch-delivered drugs.”
“We’re looking forward to working with Medherant as it progresses its patches towards the market,” said Bruno Loiseau, managing director of Laboratoires Plasto Santé. “We are expanding our patch production capacity and will support Medherant with our expertise in transdermal delivery systems as they bring TEPI Patch ibuprofen to market and begin clinical studies with other products.”